10-Q Filing

ENZON PHARMACEUTICALS, INC. CIK: 727510 Q3 2021

Filing Information

Form Type	10-Q
Accession Number	`0001410578-21-000030`
Period End Date	20210930
Filing Date	20211105
Fiscal Year	2021
Fiscal Period	Q3
XBRL Instance	enzn-20210930x10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 49 Income Statement 64 Cash Flow Statement 22 Stockholders Equity 27

Balance Sheet 49 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$47.89M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$48.14M	USD	Point-in-time
Royalty and milestone receivable	`MilestoneReceivableOnRoyaltiesCurrent`	$31.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$59.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$72.00K	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Total assets (all current)	`Assets`	$48.23M	USD	Point-in-time
Total assets (all current)	`Assets`	$47.96M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	2.96M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	2.96M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$302.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$331.00K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$110.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$46.00K	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$412.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	170.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	170.00M	shares	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$377.00K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.21M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.21M	shares	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.21M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.21M	shares	Point-in-time
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at September 30, 2021 and December 31, 2020	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at September 30, 2021 and December 31, 2020	`PreferredStockValue`	-	USD	Point-in-time
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at September 30, 2021 and December 31, 2020	`CommonStockValue`	$742.00K	USD	Point-in-time
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at September 30, 2021 and December 31, 2020	`CommonStockValue`	$742.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$76.49M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$78.01M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-71.62M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-71.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.87M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.05M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$5.81M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.34M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$5.61M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$5.58M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.36M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$5.17M	USD	Point-in-time
Total liabilities, mezzanine equity and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$48.23M	USD	Point-in-time
Total liabilities, mezzanine equity and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$47.96M	USD	Point-in-time

Income Statement 64 line items

Line Item	Tag	Value	Unit	Period
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	$18.00K	USD	3 Qtrs
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	$672.00K	USD	3 Qtrs
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	-	USD	1 Quarter
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	$8.00K	USD	1 Quarter
Total revenues	`Revenues`	-	USD	1 Quarter
Total revenues	`Revenues`	$672.00K	USD	3 Qtrs
Total revenues	`Revenues`	$8.00K	USD	1 Quarter
Total revenues	`Revenues`	$18.00K	USD	3 Qtrs
General and administrative	`OtherGeneralAndAdministrativeExpense`	$415.00K	USD	1 Quarter
General and administrative	`OtherGeneralAndAdministrativeExpense`	$901.00K	USD	3 Qtrs
General and administrative	`OtherGeneralAndAdministrativeExpense`	$910.00K	USD	3 Qtrs
General and administrative	`OtherGeneralAndAdministrativeExpense`	$228.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$910.00K	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$228.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$415.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$901.00K	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-407.00K	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-228.00K	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-883.00K	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-238.00K	USD	3 Qtrs
Other income	`OtherNonoperatingIncome`	-	USD	1 Quarter
Other income	`OtherNonoperatingIncome`	$6.00K	USD	3 Qtrs
Other income	`OtherNonoperatingIncome`	-	USD	3 Qtrs
Other income	`OtherNonoperatingIncome`	$2.00K	USD	1 Quarter
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-232.00K	USD	3 Qtrs
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-226.00K	USD	1 Quarter
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-883.00K	USD	3 Qtrs
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-407.00K	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$2.00K	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$2.00K	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-236.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-242.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-19.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-234.00K	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$11.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-226.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-407.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-885.00K	USD	3 Qtrs
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	-	USD	3 Qtrs
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	-	USD	1 Quarter
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	$506.00K	USD	1 Quarter
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	$1.52M	USD	3 Qtrs
Net loss available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-407.00K	USD	1 Quarter
Net loss available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-732.00K	USD	1 Quarter
Net loss available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-885.00K	USD	3 Qtrs
Net loss available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-1.75M	USD	3 Qtrs
Basic loss per share	`EarningsPerShareBasic`	$-0.01	USD	1 Quarter
Basic loss per share	`EarningsPerShareBasic`	$-0.02	USD	3 Qtrs
Basic loss per share	`EarningsPerShareBasic`	$-0.02	USD	3 Qtrs
Basic loss per share	`EarningsPerShareBasic`	$-0.01	USD	1 Quarter
Diluted loss per share	`EarningsPerShareDiluted`	$-0.02	USD	3 Qtrs
Diluted loss per share	`EarningsPerShareDiluted`	$-0.02	USD	3 Qtrs
Diluted loss per share	`EarningsPerShareDiluted`	$-0.01	USD	1 Quarter
Diluted loss per share	`EarningsPerShareDiluted`	$-0.01	USD	1 Quarter
Weighted-average number of shares - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	44,215.00	shares	1 Quarter
Weighted-average number of shares - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	74,215.00	shares	3 Qtrs
Weighted-average number of shares - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	74,215.00	shares	1 Quarter
Weighted-average number of shares - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	44,215.00	shares	3 Qtrs
Weighted-average number of shares - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	74,215.00	shares	1 Quarter
Weighted-average number of shares - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	74,215.00	shares	3 Qtrs
Weighted-average number of shares - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	44,215.00	shares	1 Quarter
Weighted-average number of shares - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	44,215.00	shares	3 Qtrs

Cash Flow Statement 22 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-234.00K	USD	3 Qtrs
Net loss	`ProfitLoss`	$-885.00K	USD	3 Qtrs
Changes in operating assets and liabilities	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-1.05M	USD	3 Qtrs
Changes in operating assets and liabilities	`IncreaseDecreaseInOtherOperatingCapitalNet`	$17.00K	USD	3 Qtrs
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$165.00K	USD	3 Qtrs
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-251.00K	USD	3 Qtrs
Payment of deferred stock offering expenses	`PaymentsOfStockIssuanceCosts`	$300.00K	USD	3 Qtrs
Payment of deferred stock offering expenses	`PaymentsOfStockIssuanceCosts`	-	USD	3 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-300.00K	USD	3 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	3 Qtrs
Net decrease in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-135.00K	USD	3 Qtrs
Net decrease in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-251.00K	USD	3 Qtrs
Cash beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$48.14M	USD	Point-in-time
Cash beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.45M	USD	Point-in-time
Cash beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.31M	USD	Point-in-time
Cash beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.89M	USD	Point-in-time
Cash end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$48.14M	USD	Point-in-time
Cash end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.45M	USD	Point-in-time
Cash end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.31M	USD	Point-in-time
Cash end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.89M	USD	Point-in-time
Deferred stock offering expenses	`DeferredStockOfferingExpenses`	-	USD	3 Qtrs
Deferred stock offering expenses	`DeferredStockOfferingExpenses`	$157.00K	USD	3 Qtrs

Stockholders Equity 27 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$6.87M	USD	Point-in-time
Balance	`StockholdersEquity`	$6.05M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.81M	USD	Point-in-time
Balance	`StockholdersEquity`	$6.34M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.61M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.58M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.36M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.17M	USD	Point-in-time
Net loss	`NetIncomeLoss`	$-236.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-242.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-19.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-234.00K	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$11.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-226.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-407.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-885.00K	USD	3 Qtrs
Preferred stock dividend accumulation	`DividendsCommonStockStock`	$506.00K	USD	1 Quarter
Preferred stock dividend accumulation	`DividendsCommonStockStock`	$506.00K	USD	1 Quarter
Preferred stock dividend accumulation	`DividendsCommonStockStock`	$506.00K	USD	1 Quarter
Balance	`StockholdersEquity`	$6.87M	USD	Point-in-time
Balance	`StockholdersEquity`	$6.05M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.81M	USD	Point-in-time
Balance	`StockholdersEquity`	$6.34M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.61M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.58M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.36M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.17M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.